Cardiovascular medication burden in dementia disorders: A nationwide study of 19,743 dementia patients in the Swedish Dementia Registry

Alzheimer's Research and Therapy

Volumn 6, Issue 3, 2014, Pages

  Cermakova, Pavla ^a,b   Fereshtehnejad, Seyed Mohammad ^a   Johnell, Kristina ^a   Winblad, Bengt ^a,c   Eriksdotter, Maria ^a,c   Religa, Dorota ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CHOLINESTERASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; COMORBIDITY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MIXED DEPRESSION AND DEMENTIA; MULTIINFARCT DEMENTIA; PARKINSON DISEASE DEMENTIA; PRESCRIPTION; PRIORITY JOURNAL; REGISTER;

EID: 84904020012     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt264     Document Type: Article

References (69)

1. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A, Bmj 2001 322 1447 1451 10.1136/bmj.322.7300.1447 11408299 (Pubitemid 32575406)
2. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A, Arch Neurol 2005 62 1556 1560 16216938 (Pubitemid 41434560)
3. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H, CNS drugs 2002 16 435 444 10.2165/00023210-200216070-00001 12056919 (Pubitemid 34729148)
4. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A, Stroke J Cerebr Circ 1997 28 316 321 10.1161/01.STR.28.2.316 (Pubitemid 27096997)
5. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L, Arch Intern Med 2006 166 1003 1008 10.1001/archinte.166.9.1003 16682574
6. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la Maladie d'Alzheimer Francais cohort. Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, Rolland Y, Vellas B, J Am Geriatr Soc 2013 61 1482 1488 10.1111/jgs.12415 24000874
7. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, DeKosky ST, Carlson MC, Ginkgo Evaluation of Memory (GEM) StudyInvestigators, Neurology 2013 81 896 903 10.1212/WNL.0b013e3182a35228 23911756
8. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, Crawford F, Lawlor BA, Kenny RA, Int J Geriatr Psychiat 2011 26 1038 1045 10.1002/gps.2638
9. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC, Arch Neurol 2006 63 686 692 10.1001/archneur.63.5.noc60013 16533956
10. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, White LR, Neurology 2013 81 888 895 10.1212/WNL.0b013e3182a351d4 23911753
11. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL, Neurobiol Dis 2011 41 62 70 10.1016/j.nbd.2010.08.020 20816785
12. Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats. Popovic M, Caballero-Bleda M, Popovic N, Bokonjic D, Dobric S, Int J Neurosci 1997 92 79 93 10.3109/00207459708986392 9522258
13. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J, J Am Geriatr Soc 2007 55 420 425 10.1111/j.1532-5415.2007.01071.x 17341246 (Pubitemid 46328106)
14. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R, Lancet 1998 352 1347 1351 10.1016/S0140-6736(98)03086-4 9802273 (Pubitemid 28510916)
15. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, SCOPE Study Group, J Hypertens 2003 21 875 886 10.1097/00004872-200305000-00011 12714861 (Pubitemid 36677151)
16. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Wright JW, Harding JW, Pflugers Archiv Eur J Physiol 2013 465 133 151 10.1007/s00424-012-1102-2
17. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Ashby EL, Kehoe PG, Expert Opin Invest Drugs 2013 22 1229 1242 10.1517/13543784.2013. 812631
18. Aldosterone synergizes with peripheral inflammation to induce brain IL-1β expression and depressive-like effects. Bay-Richter C, Hallberg L, Ventorp F, Janelidze S, Brundin L, Cytokine 2012 60 749 754 10.1016/j.cyto.2012. 08.016 22981168
19. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, Sueta D, Koibuchi N, Yamamoto E, Ogawa H, Kim-Mitsuyama S, FASEB J Official Public Feder Am Soc Exp Biol 2011 25 2911 2920 10.1096/fj.11-182873
20. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, Shirakura S, Kanda T, Brain Res 2010 1352 176 186 20627092
21. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with alzheimer's disease. O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, Kehoe PG, Guyatt G, Molloy DW, J Alzheimers Dis 2014 40 595 603 24496072
22. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B, BMJ 2010 340 5465 10.1136/bmj.b5465 20068258
23. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Zhou B, Teramukai S, Fukushima M, Dement Geriatr Cogn Disord 2007 23 194 201 10.1159/000099037 17259710 (Pubitemid 46333787)
24. Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Brunnstrom H, Gustafson L, Passant U, Englund E, Arch Gerontol Geriatr 2009 49 146 149 10.1016/j.archger.2008.06.005 18692255
25. The diagnosis of 'mixed' dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Rockwood K, Macknight C, Wentzel C, Black S, Bouchard R, Gauthier S, Feldman H, Hogan D, Kertesz A, Montgomery P, Ann NY Acad Sci 2000 903 522 528 10.1111/j.1749-6632.2000.tb06408.x 10818547 (Pubitemid 30251598)
26. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R, J Neurol Neurosurg Psychiatry 2003 74 720 724 10.1136/jnnp.74.6.720 12754338 (Pubitemid 36628281)
27. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Zaccai J, McCracken C, Brayne C, Age Ageing 2005 34 561 566 10.1093/ageing/afi190 16267179 (Pubitemid 41699997)
28. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, et al. Neurology 2005 65 1863 1872 10.1212/01.wnl. 0000187889.17253.b1 16237129 (Pubitemid 43970103)
29. Epidemiology, co-morbidities, and medication use of patients with Alzheimer's disease or vascular dementia in the UK. Imfeld P, Brauchli Pernus YB, Jick SS, Meier CR, JAD 2013 35 565 573 23455986
30. Prevalence of associated diseases in different types of dementia among elderly institutionalized patients: analysis of 3447 records. Holstein J, Chatellier G, Piette F, Moulias R, J Am Geriatr Soc 1994 42 972 977 8064107 (Pubitemid 24280373)
31. Co-morbidity associated with dementia. Sanderson M, Wang J, Davis DR, Lane MJ, Cornman CB, Fadden MK, Am J Alzheimers Dis Other Dement 2002 17 73 78 10.1177/153331750201700210 (Pubitemid 34754509)
32. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H, Neurology 2002 58 62 70 10.1212/WNL.58.1.62 11781407 (Pubitemid 34041939)
33. Alzheimer's disease or other dementia and medical care utilization. Eaker ED, Mickel SF, Chyou PH, Mueller-Rizner NJ, Slusser JP, Ann Epidemiol 2002 12 39 45 10.1016/S1047-2797(01)00244-7 11750239 (Pubitemid 34007351)
34. Anti-dementia drugs and co-medication amongst patients with alzheimer's disease: Investigating real-world drug use in clinical practice using the Swedish dementia quality registry (SveDem). Fereshtehnejad SM, Jonhell K, Eriksdotter M, Drugs Aging 2014 2014 2014
35. Autonomic dysfunction in dementia. Allan LM, Ballard CG, Allen J, Murray A, Davidson AW, McKeith IG, Kenny RA, J Neurol Neurosurg Psychiatry 2007 78 671 677 17178816 (Pubitemid 46998833)
36. Bradycardia in frontotemporal dementia. Robles Bayon A, Gude Sampedro F, Torregrosa Quesada JM, Neurologia 2014 29 76 85 10.1016/j.nrl.2013.02.010 23601757
37. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Postuma RB, Gagnon JF, Pelletier A, Montplaisir J, Mov. Disord Official J Mov Disord Soc 2013 28 597 604 10.1002/mds.25445
38. Swallowing dysfunction and autonomic nervous system dysfunction in alzheimer's disease: a scoping review of the evidence. Affoo RH, Foley N, Rosenbek J, Kevin Shoemaker J, Martin RE, J Am Geriatr Soc 2013 61 2203 2213 10.1111/jgs.12553 24329892
39. Medication management for people with dementia in primary care: description of implementation in the DelpHi study. Fiss T, Thyrian JR, Wucherer D, Assmann G, Kilimann I, Teipel SJ, Hoffmann W, BMC Geriatr 2013 13 121 10.1186/1471-2318-13-121 24225205
40. Adherence to medication in patients with dementia: predictors and strategies for improvement. Arlt S, Lindner R, Rosler A, von Renteln-Kruse W, Drugs Aging 2008 25 1033 1047 10.2165/0002512-200825120-00005 19021302
41. Subtypes of dementia: a study from a memory clinic in India. Alladi S, Mekala S, Chadalawada SK, Jala S, Mridula R, Kaul S, Dement Geriatr Cogn Dis 2011 32 32 38 10.1159/000329862
42. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Johnell K, Religa D, Eriksdotter M, Dement Geriatr Cogn Dis 2013 35 239 248 10.1159/000348408
43. Årsrapport SveDem 2012. [ http://www.ucr.uu.se/svedem/index.php/om- svedem/arsrapporter ]
44. World Health Organization, The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research Geneva: WHO 1993
45. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994 57 416 418 8163988
46. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ, Am J Epidemiol 2001 154 854 864 10.1093/aje/154.9. 854 11682368 (Pubitemid 33000813)
47. The association between use of cardiovascular drugs and antidepressants: a nationwide register-based study. Johnell K, Fastbom J, Eur J Clin Pharmacol 2008 64 1119 1124 10.1007/s00228-008-0541-3 18685838
48. Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+ Study. Jyrkka J, Vartiainen L, Hartikainen S, Sulkava R, Enlund H, Eur J Clin Pharmacol 2006 62 151 158 10.1007/s00228-005-0079-6 16408226
49. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M, Eur Heart J 2013 34 2585 2591 10.1093/eurheartj/eht182 23735859
50. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent. Trifiro G, Morgante L, Tari M, Arcoraci V, Savica R, J Am Geriatr Soc 2008 56 371 373 10.1111/j.1532-5415.2007.01522.x 18251828 (Pubitemid 351160673)
51. Dopamine agonists and the risk of cardiac-valve regurgitation. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E, N Eng J Med 2007 356 29 38 10.1056/NEJMoa062222 (Pubitemid 46041751)
52. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G, N Eng J Med 2007 356 39 46 10.1056/NEJMoa054830 (Pubitemid 46041752)
53. Co-morbidities of persons dying of Parkinson's disease. Lethbridge L, Johnston GM, Turnbull G, Prog Palliat Care 2013 21 140 145 10.1179/1743291X12Y. 0000000037 23843685
54. The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease. Magierski R, Kloszewska I, Sobow TM, Neurol Neurochir Pol 2010 44 139 147 20496284
55. Risk factors for dementia with Lewy bodies: a case-control study. Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, Dickson DW, Parisi J, Aakre JA, Geda YE, Knopman DS, Petersen RC, Boeve BF, Neurology 2013 81 833 840 10.1212/WNL.0b013e3182a2cbd1 23892702
56. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW, JAMA 2005 294 716 724 10.1001/jama.294.6.716 16091574 (Pubitemid 41159291)
57. Impact of gender differences on the outcome of Alzheimer's disease. Sinforiani E, Citterio A, Zucchella C, Bono G, Corbetta S, Merlo P, Mauri M, Dement Geriatr Cogn Dis 2010 30 147 154 10.1159/000318842
58. Geriatric drug therapy and healthcare utilization in the United kingdom. Kennerfalk A, Ruigomez A, Wallander MA, Wilhelmsen L, Johansson S, Ann Pharmacother 2002 36 797 803 11978154 (Pubitemid 34517406)
59. Inappropriate drug prescribing in home-dwelling, elderly patients: a population-based survey. Pitkala KH, Strandberg TE, Tilvis RS, Arch Int Med 2002 162 1707 1712 10.1001/archinte.162.15.1707
60. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. Johnell K, Weitoft GR, Fastbom J, Ann Pharmacother 2009 43 1233 1238 10.1345/aph.1M147 19584395
61. Drug therapy in the elderly: what doctors believe and patients actually do. Barat I, Andreasen F, Damsgaard EM, Br J Clin Pharmacol 2001 51 615 622 10.1046/j.0306-5251.2001.01401.x 11422022 (Pubitemid 32862751)
62. Drug use in centenarians compared with nonagenarians and octogenarians in Sweden: a nationwide register-based study. Wastesson JW, Parker MG, Fastbom J, Thorslund M, Johnell K, Age Ageing 2012 41 218 224 10.1093/ageing/afr144 22130561
63. Complex families and late-life outcomes among elderly persons: disability, institutionalization, and longevity. Pezzin LE, Pollak RA, Schone BS, J. Marriage Fam 2013 75 1084 1097 10.1111/jomf.12062 24031097
64. Living alone with dementia. Duane F, Brasher K, Koch S, Dementia (London) 2013 12 123 136 10.1177/1471301211420331 24336667
65. Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Johnell K, Fastbom J, Drugs Aging 2012 29 751 758 10.1007/s40266-012-0002-7 23018611
66. Årsrapport SveDem 2010. [ http://www.ucr.uu.se/svedem/index.php/om- svedem/arsrapporter ]
67. Net costs of dementia in Sweden-an incidence based 10 year simulation study. Skoldunger A, Wimo A, Johnell K, Int J Geriatr Psychiatry 2012 27 1112 1117 10.1002/gps.2828 22298311
68. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L, Neurology 2013 80 1888 1894 10.1212/WNL.0b013e318292a2f9 23596063
69. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafstrom M, Holmen K, Ericsson K, Backman L, Ahlbom A, Winblad B, Neurology 1991 41 1886 1892 10.1212/WNL.41.12.1886 1745343